The World Health Organization (WHO) has purchased about 4,000 vials of antivenom to treat viper and cobra bites from BPI (Insein). 

The Ministry of Industry is producing anti-venoms by doing research in cooperation with the Ministry of Health and Sports. BPI (Insein) is producing anti-venoms that can both cure venoms from both vipers and cobras. 

"About 90 percent of snakebites are related to vipers and about six percent are cobras. The remaining few percent of snakebites are due to other kinds of snakes," said an official from BPI (Insein). 

BPI anti-venoms are domestically distributed and exported to some regional countries. In the current 2018-2019 fiscal year, about 5,000 vials of anti-venom were exported. 

In the 2017-2018 fiscal year, 500 vials of anti-venom were exported on a trial basis to Cambodia and Laos. Efforts were then made to export about 5,000 vials of anti-venom. 

Of the 500 vials of anti-venoms exported last financial year, 300 vials of freeze-drying anti-venoms went to Cambodia and 200 to Laos. Each vial was priced at US$22. 

BIP (Insein) has set a target to produce up to 100,000 vials of anti-venoms as of 2018. 

In Myanmar, farmers are most vulnerable to snakebites, especially vipers.  In producing anti-venoms, both liquid form and freeze-drying are used. The latter is aimed at rural and remote areas. 

Myanmar is cooperating with Brazil in doing anti-venom research and producing anti-venoms.